Zymeworks (ZYME) Receivables (2021 - 2026)
Zymeworks recorded quarterly Receivables of $6.2 million in Q1 2026, down 15.72% quarter-over-quarter from $7.4 million in Q4 2025, and down 74.88% year-over-year from $24.8 million in Q1 2025.
Zymeworks' Receivables history runs 6 years deep, the most recent figure standing at $6.2 million for Q1 2026.
- In Q1 2026, Receivables fell 74.88% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $6.2 million (down 74.88% YoY), while the FY2025 annual figure was $7.4 million, down 86.7% from the prior year.
- Receivables came in at $6.2 million for Q1 2026 at Zymeworks, down from $7.4 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $69.9 million in Q1 2023 to a low of $3.2 million in Q2 2025.
- A 5-year average of $31.1 million and a median of $30.3 million in 2025 frame the typical range for Receivables.
- Across the five-year window, Receivables jumped 591.54% in 2023 and sank 90.03% in 2025, its largest moves.
- Zymeworks' Receivables stood at $36.4 million in 2022, then tumbled by 46.49% to $19.5 million in 2023, then jumped by 187.08% to $55.9 million in 2024, then sank by 86.78% to $7.4 million in 2025, then dropped by 15.72% to $6.2 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $6.2 million, $7.4 million, and $30.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | 6.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.23 Mn |
| Dec 31, 2025 | 7.39 Mn |
| Sep 30, 2025 | 30.32 Mn |
| Jun 30, 2025 | 3.20 Mn |
| Mar 31, 2025 | 24.79 Mn |
| Dec 31, 2024 | 55.92 Mn |
| Sep 30, 2024 | 23.70 Mn |
| Jun 30, 2024 | 32.08 Mn |
| Mar 31, 2024 | 30.95 Mn |
| Dec 31, 2023 | 19.48 Mn |
| Sep 30, 2023 | 67.27 Mn |
| Jun 30, 2023 | 48.82 Mn |
| Mar 31, 2023 | 69.92 Mn |
| Dec 31, 2022 | 36.40 Mn |
| Sep 30, 2022 | 9.73 Mn |
| Dec 31, 2021 | 15.61 Mn |